Cognition Therapeutics Received Patent for Zervimesine
The U.S. Patent and Trademark Office granted protection for a new crystalline form of the Alzheimer's drug candidate.
Updated on Oct. 13, 2026 in Alzheimer’s
Live Poll
Should pharmaceutical companies receive extended patent protection for modifying existing drug formulations?
The United States Patent and Trademark Office has issued U.S. Patent No. 12,759,979 to Cognition Therapeutics for a polymorphic crystalline form of zervimesine. This intellectual property covers production processes and methods for treating conditions including Alzheimer's disease and dementia with Lewy bodies.
Why it matters
Securing this patent facilitates the large-scale manufacturing necessary for the company to move into Phase 3 clinical trials and eventual commercialization. It also provides long-term market exclusivity for the drug candidate as the developer seeks to address neurodegenerative disorders.
The company has secured protection for its drug through 2045, supported by nearly $200 million in cumulative grants from the National Institutes of Health and various foundations. The new crystalline form is engineered to enable the large-scale manufacturing requirements for future registrational trials.
The players
Cognition Therapeutics
A clinical-stage biopharmaceutical company headquartered in Purchase, New York, that focuses on developing drugs for neurodegenerative diseases.
United States Patent and Trademark Office
The federal agency responsible for granting U.S. patents and registering trademarks.
The details
The patent protects the specific crystalline form of zervimesine that uses a pharmaceutical profile suitable for mass production. This development supports the company's planned advancement of the drug candidate into a registrational trial for patients suffering from dementia with Lewy bodies.
Timeline
Cognition Therapeutics announced the new patent issuance on October 13, 2026.
The company plans to begin manufacturing the new form of zervimesine in the first quarter of 2027.
The granted patent has a natural expiration date of 2045.
Health Landscape
The company's eligibility for a potential five-year patent extension upon FDA approval follows the standard pathways set by the Hatch-Waxman Act's patent term restoration provisions. This underscores the industry standard for leveraging intellectual property timelines to offset the high costs of long-term clinical development.
This patent marks a procedural step toward the potential availability of a new treatment option for patients with dementia with Lewy bodies and Alzheimer's. While the drug is not yet commercially available, the advancement indicates progress in the company's clinical development pipeline.
The takeaway
The issuance of this patent ensures long-term intellectual property security for a drug candidate targeting multiple neurodegenerative conditions. Patients and families can track the company's progress as it moves toward the planned manufacturing phase in early 2027.
What happens next
Cognition Therapeutics plans to begin manufacturing the new form of zervimesine in the first quarter of 2027.
Further reading
Learn more about the latest research in this field at the Alzheimer’s section.
Live Poll
Should pharmaceutical companies receive extended patent protection for modifying existing drug formulations?
